Sector News

Merck buys OncoEthix for $375m

December 19, 2014
Life sciences
Just days after announcing its mega-deal with Cubist Merck & Co is on the acquisition trial again with its sights set on private Swiss cancer biotech OncoEthix.
 
The drug giant, which is known as MSD outside the US and Canada, said today it is acquiring the firm to expand its oncology profile, taking OncoEthix’ novel oral BET (bromodomain) inhibitors – including lead candidate OTX015 – into its fold.
 
OTX015, which is currently being tested in Phase Ib studies for the treatment of haematological malignancies and advanced solid tumours, “has demonstrated early promising activity” and “strategically complements” Merck’s immuno-oncology development program, the firm said.
 
From the other side, OncoEthix said it is confident that the deal “best positions OTX015 to be developed to its full potential in areas of high unmet medical need”.
 
Under the deal, Merck will hand out an upfront payment of $110 million to OncoEthix, as well as additional milestone payments of up to $265 million if certain clinical and regulatory events are achieved.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.